Enzymotec wins Australian brain health patent

Enzymotec has won a patent in Australia for its blend of phosphatidylserine (PS) and docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA).

The patent covers methods for improving cognitive and behavioural parameters.

"The Australian market is an important market that holds a big potential for Enzymotec's products due to its dynamic nature and proximity to South East Asia," said Gil Kirtovsky, Enzymotec's business unit manager.